The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment

Cytokine

Volumn 42, Issue 3, 2008, Pages 293-297

  Kanakoudi Tsakalidou, Florence ^a   Tzimouli, Vasiliki ^a   Pratsidou Gertsi, Polyxeni ^a   Chronopoulou, Evanthia ^a   Trachana, Maria ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Anti TNF treatment; Juvenile Idiopathic Arthritis; New autoantibodies

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; CENTROMERE ANTIBODY; ETANERCEPT; HISTONE ANTIBODY; INFLIXIMAB; LA ANTIBODY; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RHEUMATOID FACTOR; RO ANTIBODY; SCL 70 ANTIBODY; SM ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HASHIMOTO DISEASE; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; MALE; NEPHELOMETRY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; INFANT; MALE; NEPHELOMETRY AND TURBIDIMETRY; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44449136850     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.01.007     Document Type: Article

References (19)

1. Charles P.J., Smeenk R.J.T., de Long J., Feldman M., and Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with Infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43 (2000) 2383-2390
2. Bobbio-Pallavicini F., Alpini C., Caporali R., Avalle S., Bugatti S., and Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term Infliximab treatment. Arthritis Res Ther 6 (2004) R264-R272
3. Errikson C., Engstrand S., Sundqvist K.-G., and Rantapaa-Dahlqvist S. Antibody formation in patients with rheumatoid arthritis treated with anti-TNF-a. Ann Rheum Dis 64 (2005) 403-407
4. Lovell D.J., Giannini E.H., Reiff A., Jones O.Y., Schneider R., Olson J.C., et al. Long-term efficacy and safety of Etanercept in children with polyarticular-course Juvenile Rheumatoid Arthritis. interim analysis from an ongoing multicenter, open-label, extended treatment trial. Arthritis Rheum 48 (2003) 218-226
5. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis: Second Revision, Edmonton, 2001. J Rheumatol 31 (2004) 390-392
6. Giannini E.H., Ruperto N., Ravelli A., Lovell D.J., Felson D.T., and Martini A. Preliminary definition of improvement in Juvenile Idiopathic Arthritis. Arthritis Rheum 40 (1997) 1202-1209
7. Cavazzana I., Franceschini F., Quinzanini M., Manera C., Del Papa N., Maglione W., et al. Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations. Clin Exp Rheumatol 24 (2006) 59-64
8. Stokes M.B., Foster K., Markowitz G.S., Ebrahimi F., Hines W., Kaufman D., et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20 (2005) 1400-1406
9. Kanakoudi-Tsakalidou F., Tzimouli V., Taparkou A., Dadaliari M., and Kopsahili O. Significance of rheumatoid factor and antinuclear antibody detection in the serum of healthy and sick children. Arch Hell Med 13 4 (1996) 291-299
10. Serra C.R., Rodrigues S.H., Silva N.P., Sztajnbok F.R., and Andrade L.E. Clinical significance of anticardiolipin antibodies in Juvenile Idiopathic Arthritis. Clin Exp Rheumatol 17 (1999) 375-380
11. Avcin T., Amborozic A., Bozic B., Acceto M., Kveder T., and Rozman B. Estimation of anticardiolipin antibodies, antibeta 2 glycoprotein antibodies and lupus anticoagulant in a prospective lingitudinal study of children with Juvenile Idiopathic Arthritis. Clin Exp Rheumatol 20 (2002) 101-108
12. Gerloni V., Pontikaki I., Gattinara M., Desiati F., Lupi E., Lurati A., et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor α monoclonal antibody, Infliximab, in persistently active refractory Juvenile Idiopathic Arthritis. Results of an open-label prospective study. Arthritis Rheum 52 (2005) 548-553
13. Cairns A.P., Duncan M.K., Hinder A.E., and Taggart A.J. New onset systemic lupus erythematosus in a patient receiving Etanercept for rheumatoid arthritis. Ann Rheum Dis 61 (2002) 1031-1032
14. Carlson E., and Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum (2003) 1165-1166
15. Ali Y., and Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med 11 (2002) 753-755
16. Marwaha R.K., Sen S., Tandon N., Sahoo M., Walia R.P., Singh S., et al. Familial aggregation of autoimmune thyroiditis in first-degree relatives of patients with juvenile autoimmune thyroid disease. Thyroid 13 (2003) 297-300
17. Stagi S., Giani T., Simonini G., and Falcini F. Thyroid function, autoimmune thyroiditis and coeliac disease in Juvenile Idiopathic Arthritis. Rheumatology (Oxford) 44 (2005) 517-520
18. Criswell L.A., Pfeifer K.A., Lum R.F., Gonzales B., Novitzke J., Kern M., et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 76 (2005) 561-571
19. Inamo Y., and Harada K. Antinuclear antibody positivity in pediatric patients with autoimmune thyroid disease. J Rheumatol 24 (1997) 576-578